These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 1595106)
1. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat. Smith SE; Meldrum BS Stroke; 1992 Jun; 23(6):861-4. PubMed ID: 1595106 [TBL] [Abstract][Full Text] [Related]
2. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Smith SE; Meldrum BS Stroke; 1995 Jan; 26(1):117-21; discussion 121-2. PubMed ID: 7839380 [TBL] [Abstract][Full Text] [Related]
3. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. Xue D; Huang ZG; Barnes K; Lesiuk HJ; Smith KE; Buchan AM J Cereb Blood Flow Metab; 1994 Mar; 14(2):251-61. PubMed ID: 7509339 [TBL] [Abstract][Full Text] [Related]
4. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, NBQX, after focal ischaemia in the rat. Smith SE; Meldrum BS Funct Neurol; 1993; 8(1):43-8. PubMed ID: 8330753 [TBL] [Abstract][Full Text] [Related]
5. A nonNMDA antagonist, GYKI 52466 improves microscopic O2 balance in the cortex during focal cerebral ischemia. Chi OZ; Chang Q; Wang G; Liu X; Weiss HR Neurol Res; 1999 Apr; 21(3):299-304. PubMed ID: 10319340 [TBL] [Abstract][Full Text] [Related]
6. A glycine site antagonist, ZD9379, reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Tatlisumak T; Takano K; Meiler MR; Fisher M Stroke; 1998 Jan; 29(1):190-5. PubMed ID: 9445350 [TBL] [Abstract][Full Text] [Related]
7. Pretreatment but not posttreatment with GYKI 52466 reduces functional deficits and neuronal damage after global ischemia in rats. Block F; Schmitt W; Schwarz M J Neurol Sci; 1996 Aug; 139(2):167-72. PubMed ID: 8856648 [TBL] [Abstract][Full Text] [Related]
8. A glycine site antagonist ZD9379 reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion. Tatlisumak T; Takano K; Meiler MR; Fisher M Acta Neurochir Suppl; 2000; 76():331-3. PubMed ID: 11450037 [TBL] [Abstract][Full Text] [Related]
9. Long-term beneficial effects of BW619C89 on neurological deficit, cognitive deficit and brain damage after middle cerebral artery occlusion in the rat. Smith SE; Hodges H; Sowinski P; Man CM; Leach MJ; Sinden JD; Gray JA; Meldrum BS Neuroscience; 1997 Apr; 77(4):1123-35. PubMed ID: 9130792 [TBL] [Abstract][Full Text] [Related]
10. Glycine site antagonist attenuates infarct size in experimental focal ischemia. Postmortem and diffusion mapping studies. Takano K; Tatlisumak T; Formato JE; Carano RA; Bergmann AG; Pullan LM; Bare TM; Sotak CH; Fisher M Stroke; 1997 Jun; 28(6):1255-62; discussion 1263. PubMed ID: 9183359 [TBL] [Abstract][Full Text] [Related]
11. In vivo neuroprotective effects of ACEA 1021 confirmed by magnetic resonance imaging in ischemic stroke. Petty MA; Neumann-Haefelin C; Kalisch J; Sarhan S; Wettstein JG; Juretschke HP Eur J Pharmacol; 2003 Aug; 474(1):53-62. PubMed ID: 12909195 [TBL] [Abstract][Full Text] [Related]
12. Intravenous brain-derived neurotrophic factor reduces infarct size and counterregulates Bax and Bcl-2 expression after temporary focal cerebral ischemia. Schäbitz WR; Sommer C; Zoder W; Kiessling M; Schwaninger M; Schwab S Stroke; 2000 Sep; 31(9):2212-7. PubMed ID: 10978054 [TBL] [Abstract][Full Text] [Related]
13. Administration of a competitive NMDA antagonist MDL-100,453 reduces infarct size after permanent middle cerebral artery occlusion in rat. Jiang N; Zhang RL; Baron BM; Chopp M J Neurol Sci; 1996 Jun; 138(1-2):36-41. PubMed ID: 8791236 [TBL] [Abstract][Full Text] [Related]
14. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Leach MJ; Swan JH; Eisenthal D; Dopson M; Nobbs M Stroke; 1993 Jul; 24(7):1063-7. PubMed ID: 8100654 [TBL] [Abstract][Full Text] [Related]
15. MRZ 2/579, a novel uncompetitive N-methyl-D-aspartate antagonist, reduces infarct volume and brain swelling and improves neurological deficit after focal cerebral ischemia in rats. Liu Y; Belayev L; Zhao W; Busto R; Ginsberg MD Brain Res; 2000 Apr; 862(1-2):111-9. PubMed ID: 10799675 [TBL] [Abstract][Full Text] [Related]
16. HU-211, a novel noncompetitive N-methyl-D-aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Belayev L; Busto R; Zhao W; Ginsberg MD Stroke; 1995 Dec; 26(12):2313-9; discussion 2319-20. PubMed ID: 7491657 [TBL] [Abstract][Full Text] [Related]
17. Effect of basic fibroblast growth factor on experimental focal ischemia studied by diffusion-weighted and perfusion imaging. Tatlisumak T; Takano K; Carano RA; Fisher M Stroke; 1996 Dec; 27(12):2292-7; discussion 2298. PubMed ID: 8969796 [TBL] [Abstract][Full Text] [Related]
18. Reduction of cerebral infarct size by non-competitive AMPA antagonists in rats subjected to permanent and transient focal ischemia. Matucz E; Móricz K; Gigler G; Simó A; Barkóczy J; Lévay G; Hársing LG; Szénási G Brain Res; 2004 Sep; 1019(1-2):210-6. PubMed ID: 15306255 [TBL] [Abstract][Full Text] [Related]
19. Effect of the non-NMDA receptor antagonist GYKI 52466 on the microdialysate and tissue concentrations of amino acids following transient forebrain ischaemia. Arvin B; Lekieffre D; Graham JL; Moncada C; Chapman AG; Meldrum BS J Neurochem; 1994 Apr; 62(4):1458-67. PubMed ID: 7907651 [TBL] [Abstract][Full Text] [Related]
20. The effect of ritanserin, a 5-HT2 receptor antagonist, on ischemic cerebral blood flow and infarct volume in rat middle cerebral artery occlusion. Takagi K; Ginsberg MD; Globus MY; Busto R; Dietrich WD Stroke; 1994 Feb; 25(2):481-5; discussion 485-6. PubMed ID: 8303760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]